Fig. 1: GALNT7 is upregulated in prostate cancer tissue.

Analysis of GALNT7 gene and protein levels in clinical prostate tissue. A GALNT7 mRNA levels in the TCGA PRAD cohort [24] are significantly higher in prostate cancer tissue relative to normal prostate tissue (n = 549, unpaired t test, p = <0.001). B Real-time PCR analysis of GALNT7 in RNA samples extracted from FFPE prostate tissue. GALNT7 is significantly upregulated in cancer relative to benign tissue (n = 12, unpaired t test, p = 0.0174). C Real-time PCR analysis of GALNT7 mRNA in matched normal and prostate tumour samples. GALNT7 is upregulated in tumour tissue relative to matched normal tissue from the same patient (n = 20, paired t test, p = 0.0357). D Immunohistochemistry analysis of GALNT7 protein in a previously published prostate cancer tissue microarray (TMA) [25]. Each section was scored using the Histoscore method [77, 78]. GALNT7 is upregulated in prostate cancer tissue relative to benign prostate hyperplasia tissue (BPH) (n = 147, unpaired t test, p < 0.001). Scale bar is 100 µm. E Immunohistochemistry analysis of GALNT7 protein in a previously published TMA containing matched tumour and normal tissue from the same patient [79]. GALNT7 protein is significantly increased in prostate tumour tissue relative to matched normal tissue from the same patient (n = 200, paired t test, p < 0.001). Scale bar is 100 µm.